Canada’s Intellectual Property Firm

Alexion files for leave to appeal to Supreme Court of Canada in case challenging constitutionality of PMPRB remedial powers

On February 5, 2018, Alexion Pharmaceuticals filed an application for leave to appeal a decision of the Federal Court of Appeal (FCA) dismissing its challenge to the constitutionality of certain of the Patented Medicine Prices Review Board (PMPRB) provisions of the Patent Act: SCC Case No. 37949. The FCA decision, Alexion Pharmaceuticals Inc v Canada (Attorney General), 2017 FCA 241, was previously reported here.